Heron Therapeutics Inc Logo Image

Heron Therapeutics Inc

Most Recent Annual Report

2015 Annual Report and Form 10K

Heron Therapeutics Inc
Order Free Hardcopy

You can request a free hardcopy of this report mailed to you by clicking the button below.

Add Annual Report

Archived Annual Reports

About Heron Therapeutics Inc

51-200 Employees
Based in Redwood City, California

Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Company's product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Company's product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The Company's other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.

Ticker:
HRTX
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
--None-- (See More --None-- Companies)
Sector:
--None-- (See More --None-- Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol